Evidence map›Paper›PMID 37612430›Full record

ArticleClinical and experimental medicine2023

Immune landscape and oncobiota in HPV-Associated Colorectal Cancer: an explorative study.

Maria Raffaella Ambrosio, Elena Niccolai, Federica Petrelli, Leandro Di Gloria, Gloria Bertacca, Andrea Giusti, Simone Baldi, Andrea Cavazzana, Matteo Palmeri, Bruno Perotti and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Clinical and experimental medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Intestinal dysbiosis and colorectal cancer.Chinese medical journal · 2025
    Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Maria Raffaella Ambrosio *Pathology Unit, Azienda USL Toscana Nord Ovest, Pisa, Italy.
Elena Niccolai *Department of Clinical and Experimental Medicine, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.
Federica PetrelliPathology Unit, Azienda USL Toscana Nord Ovest, Pisa, Italy.
Leandro Di GloriaDepartment of Biomedical, Experimental and Clinical Sciences, "Mario Serio" University of Florence, Florence, Italy.
Gloria BertaccaClinical Chemical Analysis and Immuno Allergology Department, Azienda USL Toscana Nord Ovest, Pisa, Italy.
Andrea GiustiPathology Unit, Azienda USL Toscana Nord Ovest, Pisa, Italy.
Simone BaldiDepartment of Clinical and Experimental Medicine, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.
Andrea CavazzanaPathology Unit, Azienda USL Toscana Nord Ovest, Pisa, Italy.
Matteo PalmeriSurgery Unit, Ospedale Unico Versilia, Azienda USL Toscana Nord Ovest, Pisa, Italy.
Bruno PerottiSurgery Unit, Ospedale Unico Versilia, Azienda USL Toscana Nord Ovest, Pisa, Italy.
Matteo RamazzottiDepartment of Biomedical, Experimental and Clinical Sciences, "Mario Serio" University of Florence, Florence, Italy.
Marco ArganiniSurgery Unit, Ospedale Unico Versilia, Azienda USL Toscana Nord Ovest, Pisa, Italy.
Amedeo AmedeiDepartment of Clinical and Experimental Medicine, University of Florence, Largo Brambilla 3, 50134, Florence, Italy. amedeo.amedei@unifi.it.
Azienda Usl Toscana Centro · ITUniversity of Florence · ITOspedale Versilia · ITAzienda Ospedaliero-Universitaria Careggi · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Worldwide more than 550,000 new patients suffering from malignant tumors are associated with human papillomaviruses (HPV) infection. However, only a small portion of patients infected progress to cancer, suggesting that other factors other than HPV may play a role. Some studies have investigated HPV infection in colorectal cancer (CRC) with discordant results; moreover, the role of HPV in CRC development is still unknown. We investigated HPV infection in 50 CRC from different regions, excluding the anal one, by immunohistochemistry (IHC), real-time PCR and RNA-seq. For each patient, we studied the tumor microenvironment in neoplastic and matched non-neoplastic samples, and we compared the tumor-infiltrating immune cell phenotypes among HPV-positive and negative samples. Finally, we compared the CRC-associated microbiota in HPV-positive and negative neoplastic samples by 16S rRNA sequencing. HPV infection was identified in 20% of CRC from the right side (caecum, ascending and transverse colon) and in 40% from the left side (descending colon and rectum). In all HPV-positive CRCs we found no expression of p53 and RB, thus suggesting HPV involvement in tumorigenesis. As far as the tumor microenvironment is concerned, in HPV-related cancers we observed a neoplastic environment with a reduced immune surveillance but an enhanced cytotoxic response by lymphocytes. HPV-positive and -negative CRC showed a different microbiota with lack of species normally found in CRC in the HPV-positive ones. Our results support the carcinogenic significance of HPV in CRC, suggesting a role of HPV in modulating the tumor immune microenvironment.

Indexed as

Colorectal NeoplasmsPapillomavirus InfectionsHumansRNA, Ribosomal, 16STumor MicroenvironmentRNA, Ribosomal, 16SBacteroidesColorectal cancerHuman PapillomavirusImmune evasionImmunityMicrobiotaOncobiota

Identifiers

PMID37612430
PMCPMC10725376
OpenAlexW4386113099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.